New combo therapy aims to control lung cancer spread in the chest
NCT ID NCT07482605
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with a specific type of lung cancer (EGFR-positive adenocarcinoma) that has spread to the lining of the chest, causing fluid buildup. Researchers are testing whether combining a daily targeted pill (furmonertinib) with focused chest radiation can safely control the cancer and fluid longer than the drug alone. About 63 participants will be followed to see how long the cancer stays under control and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
furmonertinib (a targeted cancer pill) and chest radiotherapy
What this could lead to
If successful, this combination could offer a new, more effective treatment option for people with EGFR-mutant lung cancer that has spread to the lining of the chest, potentially delaying disease progression.
What could go wrong
This is an early-phase trial with only 63 participants, so results may not apply to everyone. The combination may cause side effects like lung inflammation or fatigue, and it's not yet proven to be better than standard treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.